GFOR Graf Acquisition Corp. IV

Graf Acquisition Corp. IV

Blank Checks

Finance

Graf Acquisition Corp. IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in The Woodlands, Texas.

IPO Year: 2021

Exchange: NYSE

Website: grafacq.com

Recent Analyst Ratings for Graf Acquisition Corp. IV

Date	Price Target	Rating	Analyst

See more ratings

Graf Acquisition Corp. IV Press Releases

Fastest customizable press release news feed in the world

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
THE WOODLANDS, Texas, Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 25, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. The Company has decided to adjourn the Special M
9/22/23 8:31:00 AM ET
$GFOR
Blank Checks
Finance
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
THE WOODLANDS, Texas, Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 10:00 a.m., Eastern time, on September 20, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has recei
9/14/23 9:00:00 AM ET
$GFOR
Blank Checks
Finance
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
THE WOODLANDS, Texas, Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 13, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has receive
9/11/23 11:08:00 AM ET
$GFOR
Blank Checks
Finance
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR-UN, GFOR-WT))) (the "Company" or "Graf"), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.
8/30/23 7:00:00 AM ET
$GFOR
Blank Checks
Finance
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer ("NK") cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy ("SNK02"). In October 2022, the Food and Drug Administration allowed NKGen's Phase I SNK02 clinical trial to proceed per its Investigational New Drug application. NKGen previously announced a proposed business combination wit
8/24/23 8:00:00 AM ET
$GFOR
Blank Checks
Finance
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company's Securities to be Listed on Nasdaq Under Ticker Symbols "NKGN" and "NKGNW" THE WOODLANDS, Texas and SANTA ANA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") and NKGen Biotech, Inc. ("NKGen") on August 14, 2023 announced that Graf's registration statement on Form S-4 (File No. 333-271929) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with NKGen, has been declared effective by the U.S. Securities and Exchange Comm
8/15/23 12:07:51 PM ET
$GFOR
Blank Checks
Finance
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company
SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapies, and Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") today announced that Michael Klowden and Kathleen Scott have been nominated to serve as independent members of the Board of Directors (the "Board") of the post-business combination company ("New NKGen"). Assuming the director nominees are elected by the stockholders of Graf at the special meeting of its stockholders to be held
8/9/23 8:00:00 AM ET
$DRMA
$GFOR
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
Blank Checks
Finance
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. ("NKGen"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapies, and Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) ("Graf") will co-host an investor event at the Lotte New York Palace Hotel on July 20, 2023 at 10:00 AM ET. Presentation topics include NKGen's differentiated intellectual property and approach to NK cell therapy for Alzheimer's and Parkinson's diseases, NKGen's Phase 1 clinical trial data of SNK01 to treat patients with Alzheimer's disease, preclini
7/6/23 8:00:00 AM ET
$GFOR
Blank Checks
Finance
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
Graf currently has proxies from more than 65% of its stockholders to approve an extension of the time it has to close the business combination with NKGen to September 29, 2023 (the "Extension"). Votes to approve the Extension will be cast at a special meeting of Graf stockholders to be held on May 22, 2023. If the Extension is approved, Graf's sponsor to deposit additional $0.03 per non-redeeming share, per month (up to $165,000 per month in the aggregate) into Trust Account. Graf Trust Account cash to be moved to an interest-bearing account at Citibank, N.A., with initial annualized yield expected to be approximately 4.75%. No Trust Account cash or interest will be used to pay
5/16/23 9:56:00 PM ET
$GFOR
Blank Checks
Finance
NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
NKGen Biotech, Inc. ("NKGen"), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.'s non-genetically modified, enhanced and expanded NK cells have the potential to be a possible treatment for Alzheimer's and Parkinson's diseases and other neurodegenerative and oncological diseasesNKGen is expected to have a pro forma enterprise value of at least $160 million, based on $145 million in pre-money equity value plus conversion to equity at closing of at least $15 million of outstanding private convertible securities and accrued interestInitial Phase I trial data expected to be presented at the American S
4/14/23 8:19:02 PM ET
$GFOR
Blank Checks
Finance

Graf Acquisition Corp. IV

Recent Analyst Ratings for Graf Acquisition Corp. IV

Graf Acquisition Corp. IV

Recent Analyst Ratings for Graf Acquisition Corp. IV

Graf Acquisition Corp. IV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Scott Kathleen D.

SEC Form 4 filed by Kim Yong Man

SEC Form 4 filed by Song Paul Y.

SEC Form 4 filed by Gagnon Pierre

SEC Form 4 filed by Klowden Michael

Park Sangwoo gifted 2,500,000 shares (SEC Form 4)

Song Paul Y. bought $500 worth of shares (151 units at $3.30), increasing direct ownership by 0.09% to 171,121 units (SEC Form 4)

Song Paul Y. bought $850 worth of shares (268 units at $3.17), increasing direct ownership by 0.16% to 170,969 units (SEC Form 4)

Graf James A bought $2,172 worth of shares (670 units at $3.24), increasing direct ownership by 2,913% to 693 units (SEC Form 4)

Song Paul Y. bought $701 worth of shares (244 units at $2.88), increasing direct ownership by 0.14% to 170,701 units (SEC Form 4)

Graf Acquisition Corp. IV Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Song Paul Y. bought $500 worth of shares (151 units at $3.30), increasing direct ownership by 0.09% to 171,121 units (SEC Form 4)

Song Paul Y. bought $850 worth of shares (268 units at $3.17), increasing direct ownership by 0.16% to 170,969 units (SEC Form 4)

Graf James A bought $2,172 worth of shares (670 units at $3.24), increasing direct ownership by 2,913% to 693 units (SEC Form 4)

Song Paul Y. bought $701 worth of shares (244 units at $2.88), increasing direct ownership by 0.14% to 170,701 units (SEC Form 4)

Graf James A bought $67 worth of shares (23 units at $2.93) (SEC Form 4)

Song Paul Y. bought $430 worth of shares (153 units at $2.82), increasing direct ownership by 0.09% to 170,458 units (SEC Form 4)

Graf Acquisition Corp. IV SEC Filings

Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Leadership Update

Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form S-1/A filed by Graf Acquisition Corp. IV (Amendment)

SEC Form S-1/A filed by Graf Acquisition Corp. IV (Amendment)

Graf Acquisition Corp. IV Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Graf Acquisition Corp. IV

SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

SEC Form SC 13D/A filed by Graf Acquisition Corp. IV (Amendment)

SEC Form SC 13D filed by Graf Acquisition Corp. IV

SEC Form SC 13G filed by Graf Acquisition Corp. IV

SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

SEC Form SC 13G filed by Graf Acquisition Corp. IV

SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

Graf Acquisition Corp. IV Press Releases

Fastest customizable press release news feed in the world

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023

Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event

Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

Graf Acquisition Corp. IV Market Insights

Live Market Insights

Stocks That Hit 52-Week Lows On Thursday

NKGen Biotech Announces First Patient Dosed In Phase I Clinical Trial Of SNK02, Allogeneic NK Cell Therapy Product Candidate, For The Treatment Of Solid Tumors

Graf Acquisition IV, NKGen Biotech Announce Letter Of Intent For Business Combination